Deletion patterns of Duchenne and Becker muscular dystrophies in Greece

Lina Florentin, Ariadni Mavrou, Kiriaki Kekou, Catherine Metaxotou

Abstract
We present molecular data from 90 Greek boys with Duchenne or Becker muscular dystrophy using cDNA analysis or multiplex PCR or both. Deletions were detected in 63.3% of patients and were mainly clustered in two areas of the gene, one in the 3' and one in the 5' end of the gene (exons 3-19 and 44-53). Almost 17% of deletion breakpoints lay in intron 44 while 29% of deletions have a breakpoint in intron 50. Thus the distribution of deletions in our DMD/BMD patients differs from that previously reported. Furthermore a 1:4.35 proximal:distal ratio was observed in familial cases and a 1:2.45 ratio in isolated ones.

Results
Deletions were detected in 63.3% of the patients, were heterogeneous in size, and were mainly clustered around exons 44-53 and 3-19 (figure). Specifically, in 48.8% of the patients (75.8% of detectable deletions) deletions were detected primarily at the 3' end of the gene and between exons 44-53. Ten patients (17.2%) had one deletion end point between exons 44 and 45. Their DNA was further screened with microsatellite repeat STR44 which lies in intron 44. It was found that STR44 was preserved in all nine deletions starting in intron 44 but was removed in the one deletion terminating in intron 44. Seventeen deletions (29.3%) had at least one end point between exons 50 and 51. Screening with microsatellite repeat STR50 showed that of the 14 patients with a deletion ending at exon 50, STR50 was present in 13 of them (95% of these deletions stop before this marker). Furthermore STR50 was absent from three patients with a deletion of exon 51. Almost 12% of deletions involved exons 48 to 50. Only one deletion extended as far as exon 60 (figure).

In 15.5% of the patients (24.2% of detectable mutations) mutations were detected at the 5' end of the gene and were mainly clustered around exons 3-19. Seven of the deletions (12% of deletions) had an end point possibly in intron 2, while no patient had a deletion of the promoter or the first two exons of the gene. Only one deletion extended from exons 24 to 34, and was detected first with Ca1a and secondly with the use of cDNAs 4-5a and 5b-7.

A discontinuous deletion was identified with cDNA analysis, in which exons 19-21 and 26-29 were missing, while exons 22-25 were detected as a 20 kb HindIII restriction fragment. Further investigation of this patient's DNA (digestion with several restriction en-
Deletion patterns of Duchenne and Becker muscular dystrophies in Greece

Position and extent of deletions detected in Greek DMD/BMD patients using cDNA analysis or multiplex PCR or both for 18 exons of the dystrophin gene. Thin lines: deletions detected using cDNA; bold line: duplication detected with cDNA; triangles: deletions detected using PCR; JF: junction fragment.

zymes and comparison with normal male controls) excluded the possibility that this could be a junction fragment of exactly the same size as the 20 kb fragment.

A duplication was detected in our sample shown with cDNA 1-2a for exons 7-9. The duplication was identified by comparing the intensities of different bands in the same track and in the tracks of the two adjacent samples. No systematic dosage analysis was undertaken in order to detect the actual percentage in our patients.

In one patient a deletion of exon 47 was detected with both techniques but multiplex PCR detected in addition to this a deletion of exon 48 and further investigation is considered. Reduction of the annealing temperature did not succeed in amplifying exon 48. In another patient cDNA analysis showed a deletion of exons 48-50, plus an additional junction fragment. PCR did not show a deletion of exon 48, suggesting a deletion of exons 49-50, with exon 48 being present in the junction fragment.

Of the 16 boys with Becker muscular dystrophy, deletions were detected in eight cases. Three patients had deletions of exons 45-47,
and the other five had deletions of exons 38-43, 45-53, 47-48, 50-52, and 50-53. All BMD patients seemed to have a deletion in the 3' end of the gene.

In our sample there were 65 isolated and 25 familial cases and the incidence of Duchenne or Becker patients was the same in both groups. Deletions were detected in 66-2% of DMD patients and 50% of BMD patients. More deletions were detected among sporadic cases (67-6%) than familial (56%) ones. Specifically there is a 17% increase in deletions detected among isolated cases of DMD rather than among familial cases, while in Becker families there is a 15% increase of detectable deletions among familial cases. Moreover, we have observed a 1:4.35 proximal:distal ratio in Duchenne familial cases as opposed to a 1:2.45 ratio in isolated cases (table).

**Discussion**

The percentage of deletions (63-3%) detected in our DMD/BMD patients is in agreement with those reported for other populations with the exception of the Israeli study. The distribution of the observed deletions agrees with the reported ones. We have shown that 17-2% of detectable deletions had a breakpoint in intron 44 supporting previous reports of a breakpoint “hot spot” in this intron. STR44 segregated preferentially with exon 44, so the breakpoint maps distal to this marker. Although our results support that intron 44 is a breakpoint “hot spot”, the percentage of deletions detected in this area (17-2%) is lower than the 32% published. On the other hand a higher percentage (29-3%) of our patients had at least an end point in intron 50 and STR50 segregated preferentially with exon 51. Thus in our population the major deletion breakpoint “hot spot” is located proximal to this marker in intron 50 rather than in intron 44. In contrast to other reports, deletions of the promoter or the first two exons of the gene were not observed in our DMD/BMD patients. Almost 12% of detectable deletions had a breakpoint in intron 2 which could be regarded as a minor deletion “hot spot” of the 5’ end of the gene, in agreement with previous reports. The observed differences in the distribution of deletions in our sample could be explained by the hypothesis that intronless sequences could accumulate differences in different populations and that the so called “local DNA environment” might play a role in the creation of deletions and mutations.

The discontinuous deletion detected may be the result of a complex rearrangement within the gene in that particular region. Very few discontinuous deletions have been reported so far. A small increase was noted in the percentage of detectable deletions in isolated cases than familial cases but not to the extent reported by others. However, while this is true for the Duchenne cases the opposite was observed for the Becker cases and this is in contradiction to the above report. Moreover, our data do not support the hypothesis that proximal and distal deletions occur equally in familial cases and we observed that in isolated cases the ratio is much higher than the reported one.

The authors wish to thank Professors M A Ferguson-Smith, M Connor, and M Bobrow and their scientific teams for their support during the establishment of this study. This work is also indebted to Dr Steven Abb for his invaluable help, advice, and support throughout this study. The authors are grateful to all families and clinicians for providing them with blood samples and information on patients. This study was supported by the Greek Ministry of Health.

Deletion patterns of Duchenne and Becker muscular dystrophies in Greece


Deletion patterns of Duchenne and Becker muscular dystrophies in Greece.

L Florentin, A Mavrou, K Kekou and C Metaxotou

doi: 10.1136/jmg.32.1.48

Updated information and services can be found at:
http://jmg.bmj.com/content/32/1/48

**Email alerting service**

*These include:*

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/